Ocean Biomedical, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US67644C1045
USD
0.00
0 (-14.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

60.45 k

Shareholding (Mar 2025)

FII

2.16%

Held by 13 FIIs

DII

96.98%

Held by 2 DIIs

Promoter

0.00%

How big is Ocean Biomedical, Inc.?

22-Jun-2025

As of Jun 18, Ocean Biomedical, Inc. has a market capitalization of 1.71 million, with net sales of 0.00 million and a net profit of -30.72 million over the latest four quarters. Shareholder's funds are reported at -97.62 million, and total assets amount to 0.90 million.

As of Jun 18, Ocean Biomedical, Inc. has a market capitalization of 1.71 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -30.72 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -97.62 million, and total assets amount to 0.90 million.

Read More

What does Ocean Biomedical, Inc. do?

22-Jun-2025

Ocean Biomedical, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $8 million and a market cap of $1.71 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of 32.08%.

Overview:<BR>Ocean Biomedical, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 1.71 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.09<BR>- Return on Equity: 32.08%<BR>- Price to Book: -0.02<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is Ocean Biomedical, Inc. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Ocean Biomedical, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, and the stock has underperformed the S&P 500 with a year-to-date return of -98.88%.

As of 18 August 2025, the technical trend for Ocean Biomedical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show a mildly bullish signal. Bollinger Bands present a mixed view with weekly mildly bullish and monthly mildly bearish readings. The stock has significantly underperformed the S&P 500, with a year-to-date return of -98.88% compared to the S&P's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.09

stock-summary
Return on Equity

32.08%

stock-summary
Price to Book

-0.02

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-90.91%
0%
-90.91%
6 Months
-92.5%
0%
-92.5%
1 Year
-99.91%
0%
-99.91%
2 Years
-99.92%
0%
-99.92%
3 Years
-99.99%
0%
-99.99%
4 Years
-99.99%
0%
-99.99%
5 Years
0%
0%
0.0%

Ocean Biomedical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-234.26%
EBIT to Interest (avg)
-2.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.63%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.02
EV to EBIT
-2.50
EV to EBITDA
-2.50
EV to Capital Employed
-0.12
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 12 Schemes (0.86%)

Foreign Institutions

Held by 13 Foreign Institutions (2.16%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -163.08% vs 118.03% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-0.60",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.60",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "1.20",
          "chgp": "-225.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "13.00",
          "chgp": "-163.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 91.70% vs -558.05% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.80",
          "val2": "-9.30",
          "chgp": "59.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "1.80",
          "chgp": "11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.60",
          "val2": "-40.00",
          "chgp": "104.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-114.50",
          "chgp": "91.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.00
-0.60
-66.67%
Interest
0.30
0.60
-50.00%
Exceptional Items
-1.50
1.20
-225.00%
Consolidate Net Profit
-8.20
13.00
-163.08%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -163.08% vs 118.03% in Mar 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.80
-9.30
59.14%
Interest
2.00
1.80
11.11%
Exceptional Items
1.60
-40.00
104.00%
Consolidate Net Profit
-9.50
-114.50
91.70%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 91.70% vs -558.05% in Dec 2023

stock-summaryCompany CV
About Ocean Biomedical, Inc. stock-summary
stock-summary
Ocean Biomedical, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available